Overview and History of ARIMIMED 1 (Anastrozole)
ARIMIMED 1 (Anastrozole) belongs to a class of drugs called aromatase inhibitors (AIs). Aromatase inhibitors belong to an even broader class of drugs known as anti-estrogens. The other subcategory of drug under the anti-estrogens category is known as selective estrogen receptor modulators, called SERMs for short. SERMs are a class of drugs that act on the estrogen receptor (ER). Aromatase inhibitors and SERMs are very different in their action and how they deal with the issues of estrogen control. There is common misunderstanding exists that SERMs, such as NOLVAMED 20 (Tamoxifen citrate) and CLOMIMED 50 (Clomiphene citrate), serve to lower estrogen levels. This is still a popular rumor among the anabolic steroid using community.
SERMs serve to block the action of Estrogen at the receptor sites in breast tissue by occupying the receptor sites in place of Estrogen so that Estrogen itself cannot exert its effects there through receptor site binding. SERMs will also act as Estrogens at receptor sites at other cells in other areas of the body. SERMs do not lower circulating levels of Estrogen in blood plasma. Aromatase inhibitors serve to do this by eliminating the production of Estrogen through binding to and disabling the aromatase enzyme which is responsible for the conversion (or aromatization) of androgens into Estrogen.
ARIMIMED 1 (Anastrozole) was originally developed for the treatment of female patients suffering from advanced breast cancer. ARIMIMED 1 (Anastrozole)is one of the newest aromatase inhibitors, also known as a third-generation aromatase inhibitor.
Although in different ways, both aromatase inhibitors and SERMs act to block Estrogen’s effects that happens so because it has been found that the vast majority of breast cancers are stimulated and accelerated by Estrogen.
ARIMIMED 1 (Anastrozole) is used among breast cancer treatments, which is known as an adjunct treatment. Usually, that is an additional treatment in the case when other standard treatments have failed to meet proper expectations.
Estrogen plays a key role in the proper maintenance of bone and its mineral retention, and this will become significantly reduced following the vast reduction of Estrogen levels resultant of ARIMIMED 1 (Anastrozole) administration.
ARIMIMED 1 (Anastrozole) was the very first aromatase inhibitor for many bodybuilders. Nowadays it is the most popular aromatase inhibitor used among anabolic steroid users for Estrogen control. The use among the anabolic steroid using athletes is for the control of almost all Estrogen-related side effects: the manifestation of gynecomastia, water retention and bloating, rising blood pressure (as a result of water retention increases from Estrogen).
Research has shown that ARIMIMED 1 (Anastrozole) use in males has been effective enough to reduce circulating blood plasma levels of Estrogen by 50% at only a dose
of 0.5 – 1mg daily. This is a very considerable decrease in men, but those numbers differ from the 80% reduction in female breast cancer patients. We shouldn't forget the fact of how Estrogen relates to the female physiology and that it is different from males.
Some male patients suffer from abnormally high Estrogen levels of many different reasons and ARIMIMED 1 (Anastrozole) has been used in the medical field to fight that issue. ARIMIMED 1 (Anastrozole) has been used to treat male adolescents that exhibit excessive Estrogen levels during puberty, resulting in unwanted pubertal gynecomastia.
Chemical Characteristics of ARIMIMED 1 (Anastrozole)
ARIMIMED 1 (Anastrozole) is a non-steroidal aromatase inhibitor. That is important to note that it does not possess the characteristic four ring cycloalkane ring carbon structure common of all types of steroids.
Properties of ARIMIMED 1 (Anastrozole)
ARIMIMED 1 (Anastrozole) effects on serum Estrogen level control can be quite dramatic even at a dose of 1mg daily. The amount of Estrogen suppression resulting from this dose has been demonstrated to be over 80% in patients.
ARIMIMED 1 (Anastrozole) can be very effective at inhibiting the aromatase enzyme and thereby reducing Estrogen levels. ARIMIMED 1 (Anastrozole) is typically administered only to post-menopausal females, and/or utilized when other first-line treatments for breast cancer has failed.
ARIMIMED 1 (Anastrozole) and another aromatase inhibitor Letrozole, are both classified as non-steroidal and non-suicidal aromatase inhibitors that compete with the substrate for binding to the enzyme active site. Because being non-suicidal aromatase inhibitors, both compounds compete with the enzyme’s traditional ‘targets’ rather than being assured a permanent spot. Bodybuilders and athletes utilizing anabolic steroids will usually choose aromatase inhibitors such as ARIMIMED 1 (Anastrozole) because that can eliminate rising Estrogen levels at its root cause: aromatase. By disabling the aromatase enzyme, supraphysiological levels of aromatizable androgens (such as TESTOMED E 250 (Testosterone Enanthate), DIANAMED 10 (Methandienone), EQUIMED 250 (Boldenone undecylenate), etc.) cannot convert into Estrogen, thereby eliminating any possible risk of Estrogen-related side effects.
ARIMIMED 1 (Anastrozole) Side Effects
Like with any other steroid, some side effects are possible. This primarily exists in the form of excess reduction of blood plasma levels of Estrogen in the body, as well as long-term Estrogen suppression. ARIMIMED 1 (Anastrozole) affect females users much more than male users. Regarding Estrogen reduction and suppression, it must be outlined that unlike SERMs (Selective Estrogen Receptor Modulators) such as NOLVAMED 20 (Tamoxifen citrate) or CLOMIMED 50 (Clomiphene citrate), ARIMIMED 1 (Anastrozole) belongs to the family of aromatase inhibitors. Meaning that it serves to disable the aromatase enzyme, which is responsible for the aromatization or conversion of Testosterone into Estrogen. ARIMIMED 1 (Anastrozole) reduces total circulating Estrogen levels at the root source as opposed to SERMs, which serve to merely block the activity of Estrogen at select receptor sites.
There is some evidence that the use of ARIMIMED 1 (Anastrozole) results in the increased incidence and probability of experiencing bone fractures. Although this is more applicable to a female-specific side effect of ARIMIMED 1 (Anastrozole) use, Estrogen does play an important role in the promotion and retention of bone mineral content in males as well. Some studies discovered that ARIMIMED 1 (Anastrozole) does negatively impact calcium turnover levels in bone tissue with even short term use. Lethargy and fatigue are common symptoms associated with ARIMIMED 1 (Anastrozole) use.
As it happens with nearly all Estrogen reduction compounds, a reduction in circulating Estrogen levels means that the important role that Estrogen plays in the CNS (Central Nervous System) is reduced, thus resulting in possible instances of chronic fatigue. Usually, this is the result of Estrogen levels being reduced to levels that are considered far too low to be healthy.
ARIMIMED 1 (Anastrozole) has one significant side effect – that is its negative impact on blood cholesterol profiles. ARIMIMED 1 (Anastrozole) will also decrease HDL (good) cholesterol and increase LDL (bad cholesterol). This happens because Estrogen is responsible for the promotion of healthy cholesterol levels in the body, and a disruption of normal blood plasma levels of Estrogen will indeed throw that off. That is important to realize that the more severe the reduction of Estrogen, the more severe the cardiovascular impacts will be in this area.
One very importantARIMIMED 1 (Anastrozole) side effect is the possibility of Estrogen rebound. This side effect exists in particular with two of the three most popular aromatase inhibitors (ARIMIMED 1 (Anastrozole) and Letrozole). The third aromatase inhibitor, AROMAMED 25 (Exemestane) is different and does not have the possibility of Estrogen rebound. This is so because unlike AROMAMED 25 (Exemestane), ARIMIMED 1 (Anastrozole) is a non-suicidal aromatase inhibitor. ARIMIMED 1 (Anastrozole) will bind with and disable the aromatase enzyme, but it does not do it permanently. At some point, ARIMIMED 1 (Anastrozole) will dissociate with the enzyme and the enzyme will then be free to do its job again in the body.
For the users that means the risk of a rebound of Estrogen levels (and thus, Estrogen related side effects) if ARIMIMED 1 (Anastrozole) use is stopped too soon or abruptly after beginning use.
ARIMIMED 1 (Anastrozole) Cycles and Use
ARIMIMED 1 (Anastrozole) is used as a medication in the treatment of post-menopausal female breast cancer where Estrogen has been determined to be the prime cause. In such cases, the prescription dosing and administration of ARIMIMED 1 (Anastrozole) are 1mg taken once per day, until the progression of cancer has stopped.
ARIMIMED 1 (Anastrozole) For Gynecomastia and Estrogen Control On-Cycle
For this purpose, ARIMIMED 1 (Anastrozole) should be used at a general range of 0.5 – 1mg per day and can be adjusted depending on the user's tolerance and reaction to the compound. Users should manage their ARIMIMED 1 (Anastrozole) dosage according to their response. For some people, even 0.5mg/day can be too much (or too little). It should always be remembered that the purpose of the ARIMIMED 1 (Anastrozole) use is Estrogen control during a cycle, not total elimination of Estrogen levels.
ARIMIMED 1 (Anastrozole) For Post Cycle Therapy (PCT)
ARIMIMED 1 (Anastrozole) has been shown in studies to assist in the generation of endogenous natural Testosterone production in males. Therefore ARIMIMED 1 (Anastrozole) dosage of 0.5mg to 1mg per day should be sufficient for the duration of any PCT length. ARIMIMED 1 (Anastrozole) possesses a half-life of approximately 48 hours. It is important to realize that peak blood plasma levels will not be achieved with ARIMIMED 1 (Anastrozole) until a full week (7 days) of consistent use is achieved. ARIMIMED 1 (Anastrozole) can be taken at any time of day, with or without food.
Chemical info / Information
Anastrozole (AKA Arimidex)
Chemical Name: 2,2′-[5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene]bis(2-methylpropanenitrile)
Molecular Weight: 293.366 g/mol
Original Manufacturer: AstraZeneca
Elimination half-life: 46 – 48 hours (approximately 2 days)
Detection Time: 2 weeks
Anabolic Rating: N/A
Androgenic Rating: N/A